Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumabin HR-positive, Her2-positive Metastatic Breast Cancer (ASPIRE)
ASPIRE: Study of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab Metastatic Breast Cancer
Sponsor: Mt. Sinai
Enrolling: Female Patients Only
IRB Number: AAAS3060
U.S. Govt. ID: NCT03304080
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to assess the safety and effectiveness of giving anastrozole, palbociclib, trastuzumab, and pertuzumab to women with hormone receptor-positive, HER2-positive metastatic breast cancer. This combination of medications represents an all-biologic approach and avoids chemotherapy as first-line treatment of this disease.
This study is closed
Investigator
Melissa Accordino, MD
Do You Qualify?
Are you a woman of 18 years of age or older? Yes No
Have you been diagnosed with HR positive, HER2 positive, Stage IV breast cancer? Yes No
Have you had any prior systemic treatment for metastatic breast cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE